{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(5)"],"submitter":["Morales DE"],"pubmed_abstract":["Glioblastoma multiforme (GBM) is rare and fatal glioma with limited treatment options. Treatments provide minimal improvement in prognosis and only 6.8% of GBM patients have a life expectancy greater than five years. Surgical resection of this malignant glioma is difficult due to its highly invasive nature and follow-up radiotherapy with concomitant temozolomide, the currently approved standard of care, and will only extend the life of patients by a few months. It has been nearly two decades since the approval of temozolomide and there have been no clinically relevant major breakthroughs since, painting a dismal picture for patients with GBM. Although the future of GBM management seems bleak, there are many new treatment options on the horizon that propose methods of delivery to circumvent"],"journal":["Heliyon"],"pagination":["e09517"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9136349"],"repository":["biostudies-literature"],"pubmed_title":["Intranasal delivery in glioblastoma treatment: prospective molecular treatment modalities."],"pmcid":["PMC9136349"],"pubmed_authors":["Mousa S","Morales DE"],"additional_accession":[]},"is_claimable":false,"name":"Intranasal delivery in glioblastoma treatment: prospective molecular treatment modalities.","description":"Glioblastoma multiforme (GBM) is rare and fatal glioma with limited treatment options. Treatments provide minimal improvement in prognosis and only 6.8% of GBM patients have a life expectancy greater than five years. Surgical resection of this malignant glioma is difficult due to its highly invasive nature and follow-up radiotherapy with concomitant temozolomide, the currently approved standard of care, and will only extend the life of patients by a few months. It has been nearly two decades since the approval of temozolomide and there have been no clinically relevant major breakthroughs since, painting a dismal picture for patients with GBM. Although the future of GBM management seems bleak, there are many new treatment options on the horizon that propose methods of delivery to circumvent","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2025-04-04T12:45:00.121Z","creation":"2025-04-04T12:45:00.121Z"},"accession":"S-EPMC9136349","cross_references":{"pubmed":["35647354"],"doi":["10.1016/j.heliyon.2022.e09517"]}}